CurrentUnitedHealthcarePolicy N/A

Repository corticotropin (Acthar Gel / Purified Cortrophin Gel) step therapy policy

UnitedHealthcare pharmacy clinical program defining step therapy and coverage criteria for Acthar Gel (repository corticotropin injection) and Purified Cortrophin Gel (repository corticotropin injection USP), including indication-specific approval rules, required prior steroid trial or contraindication, authorization duration, and program operational notes. Effective for the program starting 2025-06-01.

Policy Summary

PayerUnitedHealthcare

PolicyRepository corticotropin (Acthar Gel / Purified Cortrophin Gel) step therapy policy

Policy CodePolicy N/A

Change TypeAdministrative updatesadded product

Effective DateJun 1, 2025

Next Review Date

Key ActionFor indications other than infantile spasms and opsoclonus-myoclonus, obtain documentation of failure, contraindication, or intolerance to corticosteroid treatment prior to authorization; authorizations for approved indications are issued for 12 months.

SourceLink

POLICY UPDATE CHANGES

Added Purified Cortrophin Gel to program with same coverage criteria as Acthar Gel (noted in historical changes March 2022).

Effective date for the 2025 program set to 2025-06-01 with P&T approval dates listed through 3/2025.

3Primary covered indications listed

12Authorization duration (months)

1Required prior trial class

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.